DIRS.INFO The most relevant business & tech news

☆ ‘I’m unable to respond:’ What it’s like to live with narcolepsy
▼ + stars: | 2024-11-01 | by ( Sandee Lamotte | ) edition.cnn.com time to read: +9 min

“What’s scary and embarrassing is that I can see people come to help me, but I’m unable to respond.”Horsnell has narcolepsy, a sleep disorder that makes it hard to stay awake for long periods. In fact, it’s estimated that only 25% of people who have narcolepsy are diagnosed and receive treatment, according to the Narcolepsy Network. “But the terrifying thing was, I’m lying in a puddle of my sweat and I’m hearing everybody whisper, ‘Is he OK? Horsnell’s experience with narcolepsy hallucinations, however, is quite different. As a trained speaker for Project Sleep’s Rising Voices of Narcolepsy leadership program, he visited the White House in 2023 to raise awareness about narcolepsy and sleep disorders.

Persons: Matthew Horsnell, ”, Horsnell, “, ” Horsnell, Jennifer Mundt, Mundt, ” Mundt, “ There’s, aren’t, orexin, Heather Lill, it’s Organizations: CNN, Northwestern University’s Feinberg School of Medicine, Narcolepsy, cataplexy, “, Narcolepsy Network, Scientists, US Food and Drug Administration, Society, Behavioral Sleep, Sleep Research Society, American Academy of Cardiovascular Sleep, White House Locations: Chicago, United States

☆ Morgan Stanley says this pharma stock can rally more than 60% thanks to its narcolepsy treatment
▼ + stars: | 2024-09-20 | by ( Pia Singh | In | ) www.cnbc.com time to read: +2 min

Centessa Pharmaceuticals could be at the forefront of a leading narcolepsy treatment that can send its shares soaring, according to Morgan Stanley. One of the company's drugs is ORX750 for the treatment of sleep-wake disorders, including narcolepsy type 1 and 2, or NT1 and NT2. Additionally, Centessa is developing ORX142 for the treatment of excessive daytime sleepiness, or EDS, in certain neurological, neurodegenerative and psychiatric disorders. The drug is designed to increase wakefulness, reduce cataplexy and potentially be a novel treatment for narcolepsy type 1. Given the firm's view of ORX750 as a now de-risked mechanism for treating narcolepsy, Hung modeled a higher peak market share for the treatment in NT1 by 2036.

Persons: Morgan Stanley, Jeffrey Hung, narcolepsy, Hung Organizations: Pharmaceuticals, IH, EDS Locations: NT1, NT2

☆ This biotech founder has a new plan to treat Tourette Syndrome, which affects 200,000 Americans each year
▼ + stars: | 2023-01-03 | by ( Yeji Jesse Lee | ) www.businessinsider.com time to read: +5 min

Emalex Bioscience is developing a new treatment for Tourette Syndrome. Tourette Syndrome currently has no cure and few treatment options. That's how in 2018 he came to found Emalex Biosciences, a pharmaceutical startup, to test a new drug for Tourette Syndrome. Emalex's drug works in a different way than other Tourette treatmentsIn spite of a tough market for biotech startups, Emalex has managed to raise $250 million from investors in November to develop its Tourette Syndrome drug candidate, called ecopipam. Many of the current approved therapies for Tourette Syndrome target D1 dopamine receptors in the brain.

Search resuls for: "cataplexy"

3 mentions found